Evidence map›Paper›PMID 24454848›Full record

ArticlePloS one2014

Human apolipoprotein e resequencing by proteomic analysis and its application to serotyping.

Motoi Nishimura, Mamoru Satoh, Satomi Nishimura, Shoko Kakinuma, Kenichi Sato, Setsu Sawai, Sachio Tsuchida, Takeshi Kazama, Kazuyuki Matsushita, Sayaka Kado and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Motoi NishimuraDepartment of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, Japan ; Division of Laboratory Medicine and Clinical Genetics, Chiba University Hospital, Chiba, Japan ; Clinical Proteomics Research Center, Chiba University Hospital, Chiba, Japan.
Mamoru SatohDepartment of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, Japan ; Clinical Proteomics Research Center, Chiba University Hospital, Chiba, Japan.
Satomi NishimuraDepartment of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, Japan.
Shoko KakinumaDepartment of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, Japan.
Kenichi SatoDivision of Laboratory Medicine and Clinical Genetics, Chiba University Hospital, Chiba, Japan.
Setsu SawaiDepartment of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, Japan ; Division of Laboratory Medicine and Clinical Genetics, Chiba University Hospital, Chiba, Japan.
Sachio TsuchidaDepartment of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, Japan.
Takeshi KazamaDivision of Laboratory Medicine and Clinical Genetics, Chiba University Hospital, Chiba, Japan.
Kazuyuki MatsushitaDepartment of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, Japan ; Division of Laboratory Medicine and Clinical Genetics, Chiba University Hospital, Chiba, Japan ; Clinical Proteomics Research Center, Chiba University Hospital, Chiba, Japan.
Sayaka KadoChemical Analysis Center, Chiba University, Chiba, Japan.
Yoshio KoderaClinical Proteomics Research Center, Chiba University Hospital, Chiba, Japan ; Laboratory of Biomolecular Dynamics, Department of Physics, School of Science, Kitasato University, Sagamihara, Japan.
Fumio NomuraDepartment of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, Japan ; Division of Laboratory Medicine and Clinical Genetics, Chiba University Hospital, Chiba, Japan ; Clinical Proteomics Research Center, Chiba University Hospital, Chiba, Japan.
Chiba University Hospital · JPChiba University · JPJapan Chemical Analysis Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundApolipoprotein E (ApoE) typing is considered important because of the association between ApoE and Alzheimer's disease and familial dyslipidemia and is currently performed by genetic testing (APOE genotyping). ApoE levels in plasma and serum are clinically determined by immunoassay.

methodsCombining an ApoE immunoassay reagent with proteomic analysis using an Orbitrap mass spectrometer, we attempted to resequence ApoE from trace amounts of serum for typing (serotyping). Most (24 of 33) ApoE mutant proteins registered to date with Online Mendelian Inheritance in Man, such as ApoE2 and ApoE4, involve lysine and arginine mutations. Digestion of mutant ApoE with trypsin will thus result in fragments that differ substantially from wild-type ApoE3 in terms of mass, making serotyping ideally suited to mass spectrometry analysis.

resultsThe mean coverage of the amino acid sequence of full-length ApoE was 91.6% in the protein resequence. Residues 112 and 158 (which are mutated in ApoE2 and ApoE4) were covered in all samples, and the protein sequences were used for serotyping. Serotypes including all heterozygous combinations (ApoE2/E3, E2/E4, E3/E4) corresponded exactly to the APOE genotyping results in each of the subjects.

conclusionOur novel ApoE serotyping method with protein resequencing requires no synthesis of stable isotope-labeled peptides or genome analysis. The method can use residual blood from samples collected for routine clinical tests, thus enabling retrospective studies with preserved body fluids. The test could be applied to samples from subjects whose DNA is unavailable. In future studies, we hope to demonstrate the capability of our method to detect rare ApoE mutations.

Indexed as

ProteomicsSequence AnalysisAmino Acid SequenceApolipoproteins EHumansImmunoassayMass SpectrometryMolecular Sequence DataSerotypingApolipoproteins E

Identifiers

PMID24454848
PMCPMC3891820
OpenAlexW2053978424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.